Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.3052W HIGH $11.05
Volume
1.50 M
Value Traded
9.71 M
Short % Float
7.9%
-0.39%Week
-10.56%1 Month
-27.06%3 Month
+49.42%6 Month
+60.33%5 Year
+60.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
751.40 M
EPS (TTM)
-1.06
P/E Ratio
-
Ent. Value
494.02 M
Total Shares
97.39 M
Float Shares
81.28 M
Insiders
16.60%
Institutions
67.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AVR Catalyst Timeline
Dated clinical, regulatory and corporate events for Anteris Technologies Global Corp.
Past FDA Catalysts and PDUFA Decisions
How AVR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Anteris Technologies Global Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AVR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DurAVR THV | severe aortic stenosis | 2025-11-17 | single digit mean gradients; large effective orifice areas (EOAs); no moderate or severe paravalvular leaks; no valve related mortality; 97% freedom from moderate or severe prosthesis-patient mismatchRead More | Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| L1 Capital Pty Ltd10% Owner | Buy | 322,940 5,200,767 held | $7.60 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AVR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.5 % (25 %) | 33.74 M | 3.43 M |
AVR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVR ranks across every disease it competes in
Competitive Position is a premium feature
See how AVR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVR News
AVRAnteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Technologies Global Corp. has secured full regulatory clearance from the French National Agency for Medicines and Health Products Safety for its DurAVR Transcatheter Heart Valve in the PARADIGM clinical trial. This authorization enables the company to begin patient recruitment in France, marking a key milestone in its global clinical strategy. The trial aims to evaluate the safety and efficacy of the DurAVR valve compared to available transcatheter aortic valve replacements, with an enrollment goal of approximately 1,000 patients. Anteris is committed to advancing treatment options for severe calcific aortic stenosis.
Read more →AVRAnteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Anteris Technologies has appointed Susan Knight and Stephen Denaro to its Board of Directors. Knight brings extensive experience from her previous roles, while Denaro returns with deep knowledge of the company. These appointments aim to strengthen governance and support the company's clinical and commercial objectives, particularly for the DurAVR® THV.
Read more →AVRAnteris Announces Results for the First Quarter of 2026
Anteris Technologies reported its Q1 2026 financial results, highlighting strong execution in the PARADIGM Trial with ongoing patient enrollment in Europe and the U.S. The company noted that recent CMS coverage will support recruitment efforts. However, they reported significant cash outflows due to clinical and regulatory expenses.
Read more →AVRAnteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies has announced the successful enrollment and treatment of the first U.S. patients in its global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve. This trial aims to evaluate the safety and effectiveness of their innovative heart valve compared to existing transcatheter aortic valve replacements. Dr. Azeem Latib has reported promising early experiences with the new valve, highlighting the trial's importance in advancing heart care. The study is aimed at enrolling approximately 1000 patients to assess various health outcomes over the course of the trial.
Read more →AVRAnteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
Anteris Technologies has announced that it secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial, which will evaluate the DurAVR® Transcatheter Heart Valve against commercially available TAVRs. This milestone is expected to enhance U.S. site activation and operational momentum. The trial aims to enroll around 1000 patients to assess the safety and effectiveness of the DurAVR® THV.
Read more →AVRAnteris Reports 2025 Financial Results and Provides Corporate Update
Anteris Technologies reported its 2025 financial results, highlighting advancements in its DurAVR product and the initiation of the PARADIGM Trial. The company aims to strengthen its position in the structural heart market while managing significant cash outflows related to clinical and regulatory needs. CEO Wayne Paterson emphasized the importance of clinical evidence and sustainable value creation.
Read more →AVRResults for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the year ended 31 December 2025 The attached Form 10-K Annual Report for the year
Anteris Technologies Global Corp. has released its Form 10-K Annual Report for the year ended December 31, 2025. The report indicates a significant decline in revenue and an increase in net losses compared to the prior year. Despite the financial challenges, Anteris is notable for its innovative DurAVR Transcatheter Heart Valve, designed to address aortic stenosis. The company continues to report on its developments and financial maneuvers in compliance with respect to ASX listing rules.
Read more →AVR▲ +8.5%on this news
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
Anteris Technologies Global Corp. will present at the TD Cowen and Barclays Healthcare Conferences. CEO Wayne Paterson will discuss the company's innovative heart devices, including the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis. The webcasts of the presentations will be available on the company's website.
Read more →AVRAnteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at $5.75 each, raising approximately $230 million. Additionally, the company completed a private placement of over 15 million shares to Medtronic, totaling around $320 million in gross proceeds. The funds will be used to advance their clinical strategy, particularly for the DurAVR® Transcatheter Heart Valve trial.
Read more →AVRAnteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Anteris Technologies has secured a $90 million strategic investment from Medtronic, contributing to a total of $320 million raised. This funding will facilitate the global pivotal PARADIGM trial for the DurAVR® Transcatheter Heart Valve (THV). Both companies aim to enhance the TAVR market through innovation and improved patient outcomes.
Read more →AVR▲ +5.4%on this newsshared move
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at $5.75 each, aiming to raise approximately $200 million. The offering is set to close on January 22, 2026, and will support the company's clinical strategy, including the DurAVR®THV global pivotal trial. Additionally, a private placement with Medtronic for up to $90 million is planned, contingent on the completion of the offering.
Read more →AVR▲ +5.4%on this newsshared move
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
Anteris Technologies Global Corp. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. The company will also engage in a private placement with Medtronic for up to $90 million. Proceeds will support the DurAVR®THV global pivotal trial and expand manufacturing capabilities.
Read more →AVRAnteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves MINNEAPOLIS, United States and BRISBANE, Australia 17 November 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASD
Anteris Technologies Global Corp. presented promising 30-day clinical outcomes from a cohort of 100 patients with severe aortic stenosis treated with the DurAVR THV valve at the PCR London Valves conference. The data revealed single-digit mean gradients and effective orifice areas, alongside no significant complications like valve-related mortality or paravalvular leaks. The results also indicated a remarkable 97% freedom from moderate or severe prosthesis-patient mismatch, offering optimism for the valve’s performance in small aortic annuli patients. The findings are expected to bolster confidence as the company progresses towards larger trials and commercialization efforts.
Read more →AVRResults for announcement to the market Name of entity: Anteris Technologies Global Corp. ("ATGC") ARBN: 677 960 235 Reporting period: For the quarter ended
Anteris Technologies Global Corp. (AVR) has filed its Form 10-Q for the quarter ending September 30, 2025, highlighting financial activities including an IPO that generated US$80 million in net proceeds. The report is essential for compliance with ASX regulations, and key business activities are also outlined. Their lead product, the DurAVR Transcatheter Heart Valve, is noted for its innovative design aimed at treating aortic stenosis. However, the report includes significant payments to related parties, which could raise governance issues.
Read more →AVRAnteris Announces Results for the Third Quarter of 2025
Anteris Technologies reported its financial results for Q3 2025, highlighting substantial progress in regulatory approvals for the PARADIGM Trial. The company received FDA approval to commence patient recruitment and secured initial European approvals. Operational readiness activities were completed, and the first patients were treated in Denmark. Anteris continues to strengthen its infrastructure to support upcoming clinical activities.
Read more →AVRFDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies has received FDA approval to initiate the PARADIGM Trial, a global clinical study evaluating the DurAVR® Transcatheter Heart Valve for patients with severe calcific aortic stenosis. The trial will compare the DurAVR® THV against existing TAVR devices, enrolling approximately 1000 patients across the U.S., Europe, and Canada. This trial is a crucial step toward securing Premarket Approval from the FDA.
Read more →AVR▼ -8.7%on this newsshared move
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Anteris Technologies announced positive one-year clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) in patients with small aortic annuli. The valve showed impressive hemodynamic performance, with no valve-related mortality and low prosthesis-patient mismatch. These results will be further validated in the upcoming PARADIGM Trial, aimed at comparing DurAVR® THV with existing TAVR options.
Read more →AVR▼ -7.8%on this newsshared move
Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") MINNEAPOLIS, United States and BRISBANE, Australia 27 October 2025: Anteris Technologies Global Corp. ( Ante
Anteris Technologies has announced the successful enrollment and treatment of the first patients in the DurAVR Transcatheter Heart Valve (THV) global pivotal trial, known as the PARADIGM Trial, which is aimed at assessing treatment options for severe calcific aortic stenosis. This trial is a significant step towards advancing the DurAVR THV towards commercialization and is expected to generate the required clinical evidence for its effectiveness. The PARADIGM Trial will enroll approximately 1,000 patients and will provide comparative data against existing transcatheter aortic valve replacements. Anteris plans to expand the trial to additional regions including the United States, Europe, and Canada.
Read more →AVRAnteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
Anteris Technologies announced that one-year clinical outcomes for its DurAVR® Transcatheter Heart Valve (THV) will be presented at TCT® 2025. The presentation will focus on outcomes in patients with small aortic annuli. The results from over 100 patients will be further evaluated in the upcoming PARADIGM Trial, which aims to compare DurAVR® THV with existing treatments.
Read more →AVR▼ -10.6%on this news· ran to -21% by day 3shared move
October 2025 NASDAQ: AVR | ASX: AVR Disclaimer This presentation has been prepared by Anteris Technologies Global Corp. ("Anteris," the "Company," "we" or "us" or "our"). This presentation, and its contents and the accom
Anteris Technologies Global Corp. has prepared a presentation for stakeholders regarding its progress and strategy in the TAVR market. The company successfully completed its U.S. IPO and is building commercial readiness for its innovative DurAVR THV, which mimics a healthy aortic valve. They have reported positive momentum in patient enrollment for their treatments and aim to disrupt the underpenetrated market for severe aortic stenosis patients. Additionally, Anteris is set to launch the pivotal PARADIGM Trial, which is targeted for the fourth quarter of 2025.
Read more →About Anteris Technologies Global Corp.
Headquarters860 BLUE GENTIAN ROAD, EAGAN, MN, 55121
BIOPHARMAWATCH ELITE PLUS
Trade the next AVR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime